A tiny molecule built from just 12 amino acids cut food intake in half for mice and pigs, without the nausea that sends many Ozempic patients running for the bathroom.
Quick Take
- Stanford Medicine researchers used artificial intelligence to identify a naturally occurring peptide called BRP that suppressed appetite in animal tests.
- A single injection cut food intake by up to 50% in mice and minipigs during the following hour, with no observed nausea or food avoidance.
- Obese mice given daily BRP shots for two weeks lost about 3 grams of body weight, almost entirely from fat, while untreated mice gained weight.
- No human trials have tested BRP yet, so its safety, dosing, and real-world effectiveness in people remain unknown.
An AI Search Turns Up A Hidden Appetite Switch
Stanford Medicine researchers didn’t stumble onto BRP by accident. They used artificial intelligence to screen for naturally occurring molecules that might act on appetite, and the search pointed them to a small, 12-amino-acid peptide the body already makes. That approach let them skip years of blind lab guessing and zero in on a candidate worth testing in live animals.
The results, published through Stanford Medicine’s own research update, describe a molecule that did something most weight-loss compounds struggle to do. It suppressed appetite in both mice and minipigs, two very different animal models, without the telltale signs of nausea or food aversion that researchers watch for closely in these studies.
The Numbers Behind The Headline
The core finding is specific and measurable. A single intramuscular shot of BRP given before feeding time reduced food intake by as much as 50% over the next hour, in both mice and minipigs. Minipigs matter here because their eating habits and metabolism track closer to humans than a mouse’s does, giving the result more weight than a single-species test would carry.
Researchers then pushed further, giving obese mice daily BRP injections for 14 days straight. Those mice lost an average of 3 grams, while a control group gained roughly the same amount. Stanford’s team reported that the weight loss came almost entirely from fat, not lean muscle or water weight, which is the outcome doctors actually want to see in a weight-loss therapy.
Why This Isn’t The First Natural Appetite Molecule Stanford Has Found
This isn’t Stanford’s first brush with a homegrown appetite suppressant. In 2022, Stanford-linked researchers identified Lac-Phe, a molecule made from lactate and phenylalanine that shows up in the body after intense exercise. In mice, it cut food intake by about 30%, and the National Institutes of Health reported similar appetite-reducing effects separately.
BRP and Lac-Phe are not the same discovery, even though both get labeled “natural Ozempic” in casual conversation. BRP is a distinct 12-amino-acid peptide found through AI screening, while Lac-Phe is an exercise-triggered metabolite from earlier research. Treating them as one story blurs two separate scientific threads that deserve to stay distinct.
What Still Has To Happen Before Any Of This Reaches A Pharmacy
None of this has been tested in people yet. Every result so far comes from mice and pigs, tested over short windows, using injections rather than a pill or any format a patient could use at home. That means dosing, long-term safety, and whether the appetite-suppressing effect holds up in humans are all open questions still waiting on clinical trials.
The word “natural” can also do a lot of quiet persuading. The Mayo Clinic and the National Center for Complementary and Integrative Health both note that naturally occurring compounds aren’t automatically safer than synthetic drugs, and some carry real risks once tested at scale. That caution applies here too, since BRP’s good behavior in animals doesn’t guarantee the same in humans.
There’s also a blunt statistical reality worth remembering. Research reviewing drug development found that more than 92% of compounds that work in animal testing fail to translate into approved human treatments, usually due to unexpected toxicity or a lack of real-world effectiveness. That doesn’t predict BRP’s fate, but it explains why Stanford’s own framing treats this as an early discovery, not a finished product. Given the stakes for millions of Americans already paying steep prices for GLP-1 drugs, a cheaper, side-effect-free alternative would be welcome news. But getting there means years of human trials, not just a promising headline.
Sources:
youtube.com, med.stanford.edu, beta.nih.gov, fiercebiotech.com, humanperformancealliance.org
